Journal: Oxidative Medicine and Cellular Longevity

Article Title: Intragastric Application of Aspirin, Clopidogrel, Cilostazol, and BPC 157 in Rats: Platelet Aggregation and Blood Clot

doi: 10.1155/2019/9084643

Figure Lengend Snippet: Rats which underwent antithrombotic agent aspirin (10 mg/kg intragastrically, once daily for three days) received immediately thereafter BPC 157 (10 μ g/kg intragastrically, once daily for three days) (white bars) or an equal volume of saline (5 ml/kg, intragastrically, once daily for three days) (gray bars); they were sacrificed at 2 h after the last application. Viscoelastic properties of the blood were assessed using modified rotational thromboelastometry (TEM) on ROTEM® delta analyzer (Tem International GmbH, Germany). Typical parameters obtained are clotting time (CT), the time from the beginning of measurement until the clot starts to form; clot formation time (CFT), the time needed for the clot to reach an amplitude of 20 mm; alpha-angle, angle of tangent at 2 mm amplitude; maximum clot firmness (MCF), the maximum amplitude of the curve during 60 minutes of measurement; Ly30, clot lysis at 30 minutes; and maximum lysis (ML) which describes the percentage of the maximum lost clot firmness relative to MCF. We analyzed the external pathway with tissue factor (EXTEM), an intrinsic pathway with ellagic acid (INTEM), or without platelet contribution with cytochalasin D (FIBTEM). After 60 minutes, CT, CFT, alpha-angle, MCF, Ly30, and ML were recorded. P > 0.05, vs. control.

Article Snippet: Viscoelastic properties of the blood were assessed using modified rotational thromboelastometry (TEM) on ROTEM® delta analyzer (Tem International GmbH, Germany).

Techniques: Modification, Coagulation, Lysis, FIBTEM Assay

Journal: Oxidative Medicine and Cellular Longevity

Article Title: Intragastric Application of Aspirin, Clopidogrel, Cilostazol, and BPC 157 in Rats: Platelet Aggregation and Blood Clot

doi: 10.1155/2019/9084643

Figure Lengend Snippet: Rats which underwent antithrombotic agent cilostazol (10 mg/kg intragastrically, once daily for three days) received immediately thereafter BPC 157 (10 μ g/kg intragastrically, once daily for three days) (white bars) or an equal volume of saline (5 ml/kg, intragastrically, once daily for three days) (gray bars); they were sacrificed at 2 h after the last application. Viscoelastic properties of the blood were assessed using modified rotational thromboelastometry (TEM) on ROTEM® delta analyzer (Tem International GmbH, Germany). Typical parameters obtained are clotting time (CT), the time from the beginning of measurement until the clot starts to form; clot formation time (CFT), the time needed for the clot to reach an amplitude of 20 mm; alpha-angle, angle of tangent at 2 mm amplitude; maximum clot firmness (MCF), the maximum amplitude of the curve during 60 minutes of measurement; Ly30, clot lysis at 30 minutes; and maximum lysis (ML) which describes the percentage of the maximum lost clot firmness relative to MCF. We analyzed external pathway with tissue factor (EXTEM), an intrinsic pathway with ellagic acid (INTEM), or without platelet contribution with cytochalasin D (FIBTEM). After 60 minutes CT, CFT, alpha-angle, MCF, Ly30, and ML were recorded. P > 0.05, vs. control.

Article Snippet: Viscoelastic properties of the blood were assessed using modified rotational thromboelastometry (TEM) on ROTEM® delta analyzer (Tem International GmbH, Germany).

Techniques: Modification, Coagulation, Lysis, FIBTEM Assay

Journal: Journal of thrombosis and haemostasis : JTH

Article Title: Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents

doi: 10.1111/jth.14148

Figure Lengend Snippet: Schematic depiction and representative examples of rotational thromboelastometry (ROTEM) traces recorded during recalcification, tissue factor (TF) and TF/tissue-type plasminogen activator (t-PA) ROTEM assays with whole blood from treated FVIII−/− rats. (A) Schematic depiction of a ROTEM curve that demonstrates where clot initiation, propagation, stabilization, lysis and dissolution of a formed thrombus can be detected. (B) Representative examples of recorded ROTEM traces from the recalcified whole blood assay, which assesses global clot formation. (C) Representative examples of recorded ROTEM traces for the TF assay, which assesses global clot formation following activation of coagulation with TF. (D) Representative examples of ROTEM traces for the TF/t-PA assay, which assesses the formation and stability of clots following addition of t-PA to all blood samples. Each trace in (B), (C) and (D) shows the rat whole blood sample that best represented its treatment group on the basis of mean clotting time and maximum clot firmness results. rFVIIa, recombinant activated factor VII; TXA, tranexamic acid; WT, wild-type.

Article Snippet: Overview of the study designs for the mouse tail vein transection bleeding studies Whole blood ROTEM assay Whole blood coagulation profiles were obtained by use of a ROTEM delta hemostasis analyzer (TEM International, Munich, Germany) and prewarmed plastic test cups.

Techniques: Lysis, Whole Blood Assay, Transcription Factor Assay, Activation Assay, Coagulation, Recombinant